Position
Squarepoint Ops LLC in Xeris Biopharma Holdings, Inc.
Back to the book · All holders of XERS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$989.8K$7.85 → $5.80
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 482.8K | $3.79M | — | — | — | 0.0% |
| Q1 2026 | 614.5K | $3.56M | $5.80 | −$989.8K | $764K | 0.0% |